Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and [beta]1-integrin signaling pathway in tumor cells

Introduction Acquired tamoxifen resistance remains the major obstacle to breast cancer endocrine therapy. [beta]1-integrin was identified as one of the target genes of G protein-coupled estrogen receptor (GPER), a novel estrogen receptor recognized as an initiator of tamoxifen resistance. Here, we i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Breast cancer research : BCR 2015-05, Vol.17
Hauptverfasser: Yuan, Jie, Liu, Manran, Yang, Li, Tu, Gang, Zhu, Qing, Chen, Maoshan, Cheng, Hong, Luo, Haojun, Fu, Weijie, Li, Zhenhua, Yang, Guanglun
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction Acquired tamoxifen resistance remains the major obstacle to breast cancer endocrine therapy. [beta]1-integrin was identified as one of the target genes of G protein-coupled estrogen receptor (GPER), a novel estrogen receptor recognized as an initiator of tamoxifen resistance. Here, we investigated the role of [beta]1-integrin in GPER-mediated tamoxifen resistance in breast cancer. Methods The expression of [beta]1-integrin and biomarkers of epithelial-mesenchymal transition were evaluated immunohistochemically in 53 specimens of metastases and paired primary tumors. The function of [beta]1-integrin was investigated in tamoxifen-resistant (MCF-7R) subclones, derived from parental MCF-7 cells, and MCF-7R [beta]1-integrin-silenced subclones in MTT and Transwell assays. Involved signaling pathways were identified using specific inhibitors and Western blotting analysis. Results GPER, [beta]1-integrin and mesenchymal biomarkers (vimentin and fibronectin) expression in metastases increased compared to the corresponding primary tumors; a close expression pattern of [beta]1-integrin and GPER were in metastases. Increased [beta]1-integrin expression was also confirmed in MCF-7R cells compared with MCF-7 cells. This upregulation of [beta]1-integrin was induced by agonists of GPER and blocked by both antagonist and knockdown of it in MCF-7R cells. Moreover, the epidermal growth factor receptor/extracellular regulated protein kinase (EGFR/ERK) signaling pathway was involved in this transcriptional regulation since specific inhibitors of these kinases also reduced the GPER-induced upregulation of [beta]1-integrin. Interestingly, silencing of [beta]1-integrin partially rescued the sensitivity of MCF-7R cells to tamoxifen and the [alpha]5[beta]1-integrin subunit is probably responsible for this phenomenon. Importantly, the cell migration and epithelial-mesenchymal transition induced by cancer-associated fibroblasts, or the product of cancer-associated fibroblasts, fibronectin, were reduced by knockdown of [beta]1-integrin in MCF-7R cells. In addition, the downstream kinases of [beta]1-integrin including focal adhesion kinase, Src and AKT were activated in MCF-7R cells and may be involved in the interaction between cancer cells and cancer-associated fibroblasts. Conclusions GPER/EGFR/ERK signaling upregulates [beta]1-integrin expression and activates downstream kinases, which contributes to cancer-associated fibroblast-induced cell migration and epithelial-mes
ISSN:1465-5411
DOI:10.1186/s13058-015-0579-y